A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 15 Jul 2024 Planned End Date changed from 30 May 2024 to 30 Dec 2024.
- 25 Oct 2023 Planned End Date changed from 30 May 2023 to 30 May 2024.
- 22 Mar 2023 Planned End Date changed from 30 Dec 2022 to 30 May 2023.